Reliance Life Sciences gets approval from SEC for the phase-I clinical trial of COVID-19 vaccine

The two-dose vaccine will need formal approval from the Drugs Controller General of India (DCGI). As per the reports, the company will be conducting trials at ten different locations in India, which will have centers in Maharashtra, Tamil Nadu, Delhi, and Andhra Pradesh. 

Royal Enfield unveiled its SG650 concept motorcycle at EICMA 2021: check the specifications
Image Source: Unsplash

The Subject Expert Committee (SEC) approved Reliance Life Sciences' application to conduct a clinical trial of its indigenous recombinant protein-based COVID-19 vaccine candidate. The company is a part of the Promoter Group of Reliance Industries Limited, owned by businessman Mukesh Ambani.

The company will reportedly start the phase-I trial. The two-dose vaccine will need formal approval from the Drugs Controller General of India (DCGI). As per the reports, the company will be conducting trials at ten different locations in India, which will have centers in Maharashtra, Tamil Nadu, Delhi, and Andhra Pradesh. 

On 24 August, HGCO19, India's first mRNA COVID-19 vaccine developed by Gennova Biopharmaceuticals, got approval from DCGI for phase-II and phase-III clinical trials. The government of India has approved six companies for Emergency Use Authorisation (EUA). So far, only three vaccines Covishield, Sputnik V, and Covaxin, are out and used in India. The Moderna, Johnson&Johnson, and Zydus Cadila vaccines are not available in India despite getting approval.